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HEPATITIS
A large population study of spontaneous HBeAg
seroconversion and acute exacerbation of chronic
hepatitis B infection: implications for antiviral therapy
M-F Yuen, H-J Yuan, C-K Hui, D K-H Wong, W-M Wong, A O-O Chan, B C-Y Wong,
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Background and aim: Clinical data on spontaneous hepatitis B e antigen (HBeAg) seroconversion
and acute exacerbation of chronic hepatitis B (CHB) virus infection from large population studies are
lacking. In the present study we examined the clinical features and significance of HBeAg seroconver-
sion and acute exacerbation in 3063 Chinese CHB patients.
Methods: Clinical assessment, liver biochemistry, hepatitis B virus (HBV) serology and HBV DNA, time
of HBeAg seroconversion, and acute exacerbation were monitored.
Results: Median age at HBeAg seroconversion was 34.5 years. The cumulative HBeAg seroconver-
sion rate significantly increased with alanine aminotransferase (ALT) levels on presentation
(p<0.0001). For patients with ALT levels more than twice the upper limit of normal (ULN) on presenta-
tion, the HBeAg seroconversion rate at the fifth year of follow up was 72.4%. After HBeAg serocon-
version, 65.2% (73/110) of patients had undetectable HBV DNA levels by the Digene Hybrid Capture
assay. Of these, 78.1% still had HBV DNA levels detectable by the Amplicor HBV Monitor Test. We
found that 37.5% antibody to HBeAg (anti-HBe) positive patients had undetectable HBV DNA levels
by the Digene Hybrid Capture assay before acute exacerbation. Acute exacerbations of longer dura-
tion, with higher peak ALT, bilirubin, and α fetoprotein levels were associated with an increased
HBeAg seroconversion rate (p<0.0001–0.045). Acute exacerbation with peak ALT levels more than
five times the ULN carried a 46.4% chance of HBeAg seroconversion within three months. HBeAg
seroreversion and mortality occurred in 2.7% and 0.7% of acute exacerbations, respectively.
Conclusion: In the present study we have provided information on HBeAg seroconversion and acute
exacerbation, which are important in decision making for CHB treatment and in designing clinical
trials.
Chronic hepatitis B (CHB) infection is a disease of globalimportance, with 400 million people being affected.1 Upto 40% of patients may develop cirrhosis related
complications and hepatocellular carcinoma (HCC).2
Hepatitis B e antigen (HBeAg) seroconversion, commonly
used as a short term end point of treatment,3 can also occur
spontaneously.4 5 Many studies have reported the rate of
HBeAg seroconversion in patients receiving treatment. The
features of spontaneous HBeAg seroconversion have also been
reported in various studies.6 7 As these data are important for
the understanding of the natural course of CHB infection, and
for the design of therapeutic trials, more information from
large population studies would be beneficial.
Acute exacerbation occurs frequently in the natural course
of CHB infection.8 9 Patients may have repeated episodes of
acute exacerbation before eventually achieving HBeAg
seroconversion.10 It is well documented that there is a positive
correlation between alanine aminotransferase (ALT) levels
during acute exacerbation and the chance of HBeAg
seroconversion.11 However, there are few studies on other pre-
dictive factors in acute exacerbation favouring spontaneous
HBeAg seroconversion.12 13 Acute exacerbation also occurs in
patients who are antibody to HBeAg (anti-HBe) positive with
some patients having HBeAg seroreversion afterwards.14 Acute
exacerbation can infrequently lead to hepatic decompensation
and mortality.15
In this study, we present epidemiological data from a large
population of Chinese CHB patients with respect to HBeAg
seroconversion and acute hepatitis B virus (HBV) exacerba-
tion.
PATIENTS AND METHODS
From 1976 to 2000, 3063 patients attending the Hepatitis
Clinic, Queen Mary Hospital, University of Hong Kong, Hong
Kong, were recruited into the present study. Patients were all
hepatitis B surface antigen (HBsAg) positive for at least six
months. Patients were excluded from the study if they had any
of the following conditions: (1) cirrhosis related complications
or HCC on presentation, (2) treatment for CHB at any time, (3)
concomitant hepatitis C or D virus infection, (4) evidence of
autoimmune hepatitis, Wilson’s disease, or primary biliary
cirrhosis, (5) history of heavy alcoholic intake, (6) evidence of
fatty liver, and (7) intake of any hepatotoxic drugs. Patients
had complete history enquiry and physical examination dur-
ing the first clinic visit. Blood was taken for liver biochemistry,
α fetoprotein (AFP), and HBV serological markers, including
HBsAg, HBeAg, and anti-HBe by microparticle enzyme
immunoassay (MEIA; Abbott Laboratories, Chicago, Illinois,
USA) during the first visit and every subsequent visit which
was scheduled at intervals of 3–6 months, or more frequently
whenever indicated.
HBeAg seroconversion was defined as loss of HBeAg with
development of anti-HBe on at least two consecutive follow
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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B virus; AFP, α fetoprotein; ULN, upper limit of normal; PCR, polymerase
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ups. In patients who had HBeAg seroconversion, HBeAg sero-
reversion was defined as subsequent loss of anti-HBe and
regaining of HBeAg on at least two consecutive follow ups.
Acute HBV exacerbation was defined as an increase in ALT
to more than 1.5 times the upper limit of normal (ULN) after
excluding other common causes of ALT elevation, including
other viral hepatitis, drug induced hepatitis, alcoholic hepati-
tis, and steatohepatitis. Time, duration, peak ALT level, peak
AFP, peak bilirubin level, and HBeAg/anti-HBe status were all
monitored during HBV exacerbation. HBeAg seroconversion
was regarded as related to acute exacerbation if HBeAg sero-
conversion occurred within three months of acute exacerba-
tion.
HBV DNA levels before and after HBeAg seroconversion
were measured in 110 patients by Digene Hybrid Capture
assay (Digene Corporation, Gaithersburg, Maryland, USA)
(lower limit of detection 140 000 copies/ml). For those with
undetectable HBV DNA levels by the above assay, HBV DNA
levels were determined again by a more sensitive quantitative
polymerase chain reaction (PCR) assay (Cobas Amplitor HBV
Monitor Test; Roche Diagnostics, Branchburg, New Jersey,
USA) (lower limit of detection 200 copies/ml).
Statistical analysis
All statistical analyses were performed using the Statistical
Program for Social Sciences (SPSS 10.0 for Windows, SPSS
Inc., Chicago, Illinois, USA). Data were analysed by Mann-
Whitney test for continuous ordinal data. Differences in paired
parameters were tested by theWilcoxon signed ranks test. The
Kaplan-Meier method was applied for calculation of the
cumulative rate of HBeAg seroconversion and the cumulative
risk of acute HBV exacerbation using the log rank test. A p
value of less than 0.05 was considered statistically significant.
RESULTS
Demographic data on presentation for the 3063 patients are
listed in table 1.
Of the 1215 patients who were HBeAg positive on presenta-
tion, 493 (40.6%) underwent HBeAg seroconversion during
the follow up period. Median age at HBeAg seroconversion
was 34.5 years (range 3.6–77.4). There was no difference in the
cumulative HBeAg seroconversion rate between male and
female patients (p=0.53).
The cumulative HBeAg seroconversion rate was studied by
stratifying patients according to ALT levels on presentation:
group 1 patients had ALT levels <0.5×ULN; group 2 patients
had ALT levels >0.5–1×ULN; group 3 patients had ALT levels
>1–2×ULN; group 4 patients had ALT levels >2–5×ULN; and
group 5 patients had ALT levels >5×ULN.Higher ALT levels on
presentation were associated with a higher chance of HBeAg
seroconversion (overall p<0.0001) (fig 1). Cumulative HBeAg
seroconversion rates according to the different ALT levels on
presentation are listed in table 2.
In 110 patients with paired sera before and after HBeAg
seroconversion, median HBV DNA level was significantly
lower after HBeAg seroconversion than before HBeAg
seroconversion (<0.142 (range <0.142–309.5×106) v 4.01
(range <0.142–803.9×106) copies/ml; p<0.0001). Seventy
three patients (65.2%) had undetectable HBV DNA by the
Digene Hybrid Capture assay after HBeAg seroconversion.
However, when sera of these 73 patients were retested using
the Cobas Amplicor HBV Monitor Test, only 16 (21.9%) had
undetectable HBV DNA. The median HBV DNA level of the
remaining 57 patients was 3150 copies/ml (range 200–327 000
000). HBV DNA levels were in the range 200–103, >103–104,
>104–105, and >105 in 11 (15.1%), 17 (23.3%), 25 (34.2%), and
4 (5.5%) patients, respectively.
A total of 1670 patients (54.5%) had ALT levels less than
1.5×ULN throughout the whole follow up period—that is,
more than half of the Chinese CHB patients had near normal
ALT levels over a prolonged period of time. The remaining
1393 patients (45.5%) (765 HBeAg positive, 628 anti-HBe
positive) had at least one episode of acute exacerbation (929
on presentation and 464 on subsequent follow up). Only 204
patients (14.6%) experienced hepatitis symptoms. Excluding
the 929 patients with acute exacerbation on presentation, the
cumulative risk of acute exacerbation during follow up is
illustrated in fig 2.
Of the 765 HBeAg positive patients with acute exacerbation,
297 patients (38.8%) had HBeAg seroconversion within three
months of acute exacerbation. The differences in the factors of
acute exacerbation between patients with and without HBeAg
seroconversion are listed in table 3. (For patients who
presented with acute exacerbation, the earliest parameters
were taken as peak values if subsequent values were not
increasing.) HBeAg seroreversion occurred in 17 of 628
anti-HBe positive patients (2.7%) after acute exacerbation.
There were no differences in median peak ALT levels, peak
bilirubin levels, peak AFP levels, and duration of acute exacer-
bation between anti-HBe positive patients with and without
HBeAg seroreversion. Ten patients (0.7%) died from acute
exacerbation due to hepatic decompensation.
The chance of HBeAg seroconversion within three months
of acute exacerbation in patients with peak ALT levels
1.5–2×ULN, >2–5×ULN, and > 5×ULN were 27.2%, 35.6%,
and 46.4%, respectively. The chance of HBeAg seroconversion
Table 1 Demographic data for the study population
on presentation
No of patients 3063
Age at presentation (y) 38 (1–85)
Sex (M:F) 1985: 1078
HBeAg:anti-HBe 1215: 1826*
Albumin (g/l) 45 (18–58)
ALT (U/l) 42 (4–6820)
Bilirubin (µmol/l) 11 (1–553)
AFP (ng/ml) 4 (1–4991)
Duration of follow up (months) 29 (0.6–291)
Values are median (range) or number.
*22 patients were negative for both HBeAg and anti-HBe at
presentation.
HBeAg, hepatitis B e antigen; anti-HBe, antibody to HBeAg; ALT,
alanine aminotransferase; AFP, α fetoprotein.
Figure 1 Cumulative rates of hepatitis B e antigen (HBeAg)
seroconversion in different groups of patients stratified according to
levels of alanine aminotransferase (ALT) on presentation: group 1,
ALT <0.5×upper limit of normal (ULN); group 2, ALT >0.5–1×ULN;
group 3, ALT >1–2×ULN; group 4, ALT >2–5×ULN; and group 5,
ALT >5×ULN.
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within three months of acute exacerbation in patients with
peak AFP levels of <20, >20–100, and >100 ng/ml were
35.2%, 43.6%, and 50.5%, respectively. Of 336 patients with
peak ALT levels >5×ULN and 91 patients with peak AFP lev-
els >100 ng/ml, 70 patients had both of the above parameters.
Forty of these 70 patients (57.1%) had HBeAg seroconversion
within three months of acute exacerbation.
Compared with anti-HBe positive patients, HBeAg positive
patients had significantly higher median peak ALT levels (148
(range 75–8000) v 218 (75–3990) U/l, respectively; p<0.0001),
higher median peak AFP levels (5 (range 1–2867) v 8 (1–3958)
U/l, respectively; p<0.0001), and longer median duration of
acute exacerbation (17 (range 3–416) v 21 (2–436) weeks,
respectively; p=0.011).
HBV DNA levels within three months prior to acute exacer-
bation were measured in 46 HBeAg positive patients (14 with
HBeAg seroconversion and 32 without HBeAg seroconversion
after acute exacerbation) and 32 anti-HBe positive patients. In
HBeAg positive patients, there was a trend for patients with
HBeAg seroconversion to have lower HBV DNA levels before
acute exacerbation compared with patients who did not
achieve HBeAg seroconversion (29.0 (range 0.26–817.7×106) v
241.8 (range 0.27–1700×106) copies/ml; p=0.073). Themedian
HBV DNA level was significantly higher in HBeAg positive
patients compared with that of anti-HBe positive patients
(182.2 (range 0.26–1700) v 0.31 (<0.142–407.0)×106 copies/
ml, respectively; p<0.0001). All 46 HBeAg positive patients
had detectable HBV DNA levels above 0.142×106 copies/ml
(lower limit of detection of Digene Hybrid Capture assay)
whereas 12 anti-HBe positive patients (37.5%) had HBV DNA
levels below 0.142×106 copies/ml within three months prior to
acute exacerbation. Of these 12 patients, 11 (91.7%) had
detectable HBV DNA, ranging from 537 to 45 400 copies/ml,
and one patient (8.3%) had undetectable HBV DNA by the
Amplicor HBV Monitor Test.
DISCUSSION
This large population study has provided essential infor-
mation on the probability of HBeAg seroconversion when
assessing patients on presentation. The overall HBeAg
seroconversion rate was 18% and 53.5% for the first and fifth
years, respectively (table 2). In general, the higher the ALT
level on presentation, the higher the chance of HBeAg
seroconversion during subsequent follow up. Table 2 provides
a guide for the design of therapeutic trials whereby one can
balance the chance of spontaneous HBeAg seroconversion and
the chance of HBeAg seroconversion induced by treatment.
Even when mild elevation of ALT levels to above 1.5×ULN
was taken as acute exacerbation, 54% of patients still did not
have any exacerbation throughout their follow up period.
Therefore, unlike in Caucasian CHB patients, Chinese CHB
patients often had normal or near normal ALT levels. Various
factors during acute exacerbation were identified as predis-
posing patients to HBeAg seroconversion. Patients with peak
ALT levels > 5×ULN and peak AFP levels >100 ng/ml had a
57.1% chance of HBeAg seroconversion within three months
of occurrence of acute exacerbation. These two parameters
may reflect, respectively, the degree of immune mediated
attack on infected hepatocytes and hepatocyte regeneration
afterwards. Additional information that has not been well
studied in the past was duration of acute exacerbation. We
Table 2 Cumulative hepatitis B e antigen (HBeAg) seroconversion rates in patients
with different alanine aminotransferase levels on presentation
Cumulative HBeAg seroconversion rate (%)
Year 1 Year 2 Year 3 Year 4 Year 5
All patients (n=1215) 18.0 31.0 41.3 47.6 53.5
Stratified by ALT levels on presentation
ALT <0.5×ULN (n=151) 9.4 16.0 19.9 23.0 26.5
ALT >0.5–1×ULN (n=294) 11.7 22.6 32.3 39.5 47.9
ALT >1–2×ULN (n=284) 12.8 28.9 40.1 46.2 53.0
ALT >2×ULN (n=486) 28.2 44.9 58.4 66.6 72.4
ALT >2–5×ULN (n=243) 24.9 39.5 53.5 59.8 67.5
ALT >5×ULN (n=243) 31.5 50.6 63.7 74.7 78.1
ALT, alanine aminotransferase; ULN, upper limit of normal.
Figure 2 Cumulative risk of acute exacerbation during follow up in
464 patients.
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Table 3 Parameters of acute exacerbation in patients with and without hepatitis B e
antigen (HBeAg) seroconversion
Acute exacerbation with
HBeAg seroconversion
(n=297)
Acute exacerbation without
HBeAg seroconversion
(n=468) p Value
Peak ALT (U/l) 279 (75–3990) 191 (75–3955) <0.0001
Peak bilirubin (µmol/l) 17 (4–390) 15 (2–868) 0.045
Peak AFP (ng/ml) 10 (1–3958) 7 (1–2015) 0.001
Duration of acute exacerbation
(weeks)
24 (1–236) 17 (1–436) 0.018
All values are median (range).
ALT, alanine aminotransferase; AFP, α fetoprotein.
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found that patients with a longer duration of acute exacerba-
tion had a higher chance of HBeAg seroconversion subse-
quently (table 3).
Mortality due to acute exacerbation was uncommon, occur-
ring in only 0.7% of patients. These data do not suggest that
treatment with lamivudine or interferon-alpha for patients
with acute HBV exacerbation is indicated routinely. In fact, the
high rate of spontaneous HBeAg seroconversion should be
borne in mind when one is considering initiation of treatment
for patients with very high ALT levels. Evans et al have
commented from their study of 454 Asian-Americans that
“high rate of spontaneous seroconversion should be weighted
in decisions to treat HBV carriers with interferon-alpha”.6 For
patients with ALT levels >2×ULN, the cumulative spontane-
ous HBeAg seroconversion rate was 72.4% by the end of five
years (table 2). This is similar to the HBeAg seroconversion
rate for patients on five years of continuous lamivudine.16 It is
unfortunate that the lamivudine study did not have a five year
placebo arm, but with the data from the present study it is
difficult to conclude that lamivudine therapy is of benefit, at
least as far as long term cumulative HBeAg seroconversion is
concerned. Lamivudine is however useful in decreasing
necroinflammation and improving fibrosis.17–19 In addition,
this study also showed that HBeAg seroreversion occurred in
only 2.7% of anti-HBe positive patients undergoing acute
exacerbation. This suggests that spontaneous HBeAg serocon-
version was very stable in Chinese CHB patients.
Although all HBeAg positive patients with available serum
tested for HBV DNA with acute exacerbation had HBV DNA
levels of more than 105 copies/ml within three months of acute
exacerbation, 37.5% anti-HBe positive patients had HBV DNA
levels lower than 105 copies/ml within three months of acute
exacerbation (91.7% still had detectable HBV DNA level by the
Amplicor PCR assay). Acute exacerbation could therefore
occur in anti-HBe positive patients with a very low HBV DNA
titre. This also suggests that Chinese anti-HBe positive
patients with low HBV DNA levels are not necessarily in the
quiescent phase of HBV infection. The study of Hsu et al con-
firms that a proportion of anti-HBe positive patients continue
to have disease progression. Hepatitic flares associated with
low HBV DNA levels in anti-HBe positive patients would lead
to continuing liver damage, resulting in the development of
cirrhosis and cirrhosis related complications in these
patients.7 20 That these exacerbations are equally likely to be
due to wild-type virus and precore mutants has been reported
by us and other groups previously.21–23 Anti-HBe positive
patients should be monitored as carefully as HBeAg positive
patients for the development of cirrhosis related complica-
tions and HCC. In addition, the majority of patients after
HBeAg seroconversion still had detectable HBV DNA levels
measured by the PCR assay. HBV DNA was detectable by the
Cobas Amplicor HBV Monitor Test in 78.1% of patients with
HBV DNA undetectable by the Digene Hybrid Capture assay.
This raises the issue of whether the end point of CHB
treatment should be HBeAg seroconversion. Amore prolonged
and maximal suppression of HBV DNA, even after HBeAg
seroconversion, to maintain improvement in necroinflamma-
tion and fibrosis would appear to be a more logical approach.
In conclusion, the present large population study has
provided essential epidemiological and clinical data on HBeAg
seroconversion and acute HBV exacerbation in chronic
hepatitis B infection. This information may be important in
decision making for the treatment of HBV and in designing
clinical trials.
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